Inhibition of Respiratory Syncytial Virus Infection with the CC Chemokine RANTES (CCL5)

Journal of Medical Virology

Volumn 73, Issue 2, 2004, Pages 300-308

  Elliott, Matthew B ^a   Tebbey, Paul W ^a,b   Pryharski, Karin S ^a   Scheuer, Catherine A ^a   Laughlin, Todd S ^a,c   Hancock, Gerald E ^a  

^a WYETH RESEARCH   (United States)

^b CENTOCOR INC   (United States)

^c Ortho Clinical Diagnostics Inc   (United States)

Author keywords

Antiviral; Chemokine; Prophylaxis; RANTES CCL5; Respiratory syncytial virus (RSV)

Indexed keywords

BETA CHEMOKINE; PALIVIZUMAB; RANTES; RECOMBINANT CCL5; RECOMBINANT CYTOKINE; RIBAVIRIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANTIBODY DETECTION; ARTICLE; CELL INTERACTION; CHILD; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; EPITHELIUM CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROPHOBICITY; IMMUNE DEFICIENCY; IMMUNOMODULATION; IMMUNOTHERAPY; INFANT; INHIBITION KINETICS; PROTEIN EXPRESSION; PROTEIN INTERACTION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT INFECTION; RISK BENEFIT ANALYSIS; VIRUS ADSORPTION; VIRUS MUTATION;

ANTIVIRAL AGENTS; CELL LINE, TUMOR; CHEMOKINES, CC; CHEMOKINES, CXC; EPITHELIAL CELLS; HUMANS; MACROPHAGE INFLAMMATORY PROTEIN-1; MONOCYTE CHEMOATTRACTANT PROTEINS; MONOKINES; RECEPTORS, CCR5; RECEPTORS, CHEMOKINE; RECOMBINANT PROTEINS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; VIRAL FUSION PROTEINS; VIRUS REPLICATION;

RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS;

EID: 2142715274     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.20091     Document Type: Article

References (63)

1. Akerlind B, Norrby E, Orvell C, Mufson MA. 1988. Respiratory syncytial virus: Heterogeneity of subgroup strains. J Gen Virol 69:2145-2154.
2. Appay V, Rowland-Jones SL. 2001. RANTES: A versatile and controversial chemokine. Trends Immunol 22:83-87.
3. Baggiolini M. 2001. Chemokines in pathology and medicine. J Intern Med 250:91-104.
4. Bartz H, Turkel O, Hoffjan S, Rothoeft T, Gonschorek A, Schauer U. 2003. Respiratory syncytial virus decreases the capacity of myeloid dendritic cells to induce interferon-gamma in naive T cells. Immunology 109:49-57.
5. Beaulieu S, Robbiani DF, Du X, Rodrigues E, Ignatius R, Wei Y, Ponath P, Young JW, Pope M, Steinman RM, Mojsov S. 2002. Expression of a functional eotaxin (CC chemokine ligand 11) receptor CCR3 by human dendritic cells. J Immunol 169:2925-2936.
6. Becker S, Reed W, Henderson FW, Noah TL. 1997. RSV infection of human airay epithelial cells causes production of the beta chemokine RANTES. Am J Physiol 272:L512-520.
7. Berger EA, Murphy PM, Farber JM. 1999. Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism and disease. Annu Rev Immunol 17:657-700.
8. Blanpain C, Vanderwinden JM, Cihak J, Wittamer V, Le Poul E, Issafras H, Stangassinger M, Vassart G, Marullo S, Schlndorff D, Parmentier M, Mack M. 2002. Multiple active states and oligomerization of CCR5 revealed by functional properties of monoclonal antibodies. Mol Biol Cell 13:723-737.
9. Bonville CA, Rosenberg HF, Domachowske JB. 1999. Macrophage inflammatory protein-1-alpha and RANTES are present in nasal secretions during ongoing upper respiratory tract infection. Pediatr Allergy Immunol 10:39-44.
10. Bourgeois C, Bour JB, Lidholt K, Gauthray C, Pothier P. 1998. Heparin-like structures on respiratory syncytial virus are involved in its infectivity in vitro. J Virol 72:7221-7227.
11. Crowe JE, Jr., Bui PT, Davis AR, Chanock RM, Murphy BR. 1994. A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees. Vaccine 12:783-790.
12. Crowe JE, Jr., Bui PT, Firestone CY, Connors M, Elkins WR, Chanock RM, Murphy BR. 1996. Live subgroup B respiratory syncytial virus vaccines that are attenuated, genetically stable, and immunogenic in rodents and nonhuman primates. J Infect Dis 173:829-839.
13. Dairaghi DJ, Greaves DR, Schall TJ. 1998. Abduction of chemokine elements by herpesviruses. Sem Virol 8:377-385.
14. Domachowske JB, Rosenberg HF. 1999. Respiratory syncytial virus infection: Immune response, immunopathogenesis, and treatment. Clin Microbiol Rev 12:298-309.
15. Dorig RE, Marcil A, Chopra A, Richardson CD. 1993. The human CD46 is a receptor for measles virus (Edmonston strain). Cell 75:295-305.
16. Dorner BG, Scheffold A, Rolph MS, Huser MB, Kaufmann SH, Radbruch A, Flesch IE, Kroczek RA. 2002. MIP-1alpha, MIP-1beta, RANTES, and ATAC/lymphotactin function together with IFN-gamma as type 1 cytokines. Proc Natl Acad Sci USA 99:6181-6186.
17. Eddleston J, Christiansen SC, Zuraw BL. 2002. Functional expression of the C-X-C chemokine receptor CXCR4 by human bronchial epithelial cells: Regulation by proinflammatory mediators. J Immunol 169:6445-6451.
18. Elliott MB, Pryharski KS, Yu Q, Parks CL, Laughlin TS, Gupta CK, Lerch RA, Randolph VB, LaPierre NA, Heers Dack KM, Hancock GE. 2004. Recombinant respiratory syncytial viruses lacking the C-terminal third of the attachment (G) protein are immunogenic and attenuated in vivo and in vitro. J Virol (in press).
19. Feldman SA, Hendry RM, Beeler JA. 1999. Identification of a linear heparin binding domain for human respiratory syncytial virus attachment glycoprotein G. J Virol 73:6610-6617.
20. Feldman SA, Audet S, Beeler JA. 2000. The fusion glycoprotein of human respiratory syncytial virus facilitates virus attachment and infectivity via an interaction with cellular heparan sulfate. J Virol 74:6442-6447.
21. Gorman JJ, McKimm-Breschkin JL, Norton RS, Barnham KJ. 2001. Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein. J Biol Chem 276:38988-38994.
22. Hall CB. 2001. Respiratory syncytial virus and parainfluenza virus. N Engl J Med 21:344:1917-1928.
23. Hallak LK, Collins PL, Knudson W, Peeples ME. 2000. Iduronic acid-containing glycosaminoglycans on target cells are required for efficient respiratory syncytial virus infection. Virology 271:264-275.
24. Hancock GE, Speelman DJ, Heers K, Bortell E, Smith J, Cosco C. 1996. Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus. J Virol 70:7783-7791.
25. Harrison AM, Bonville CA, Rosenberg HF, Domachowske JB. 1999. Respiratory syncytial virus-induced chemokine expression in the lower airways: Eosinophil recruitment and degranulation. Am J Resp Crit Care Med 159:1918-1924.
26. Hickling TP, Bright H, Wing K, Gower D, Martin SL, Sim RB, Malhotra R. 1999. A recombinant trimeric surfactant protein D carbohydrate recognition domain inhibits respiratory syncytial virus infection in vitro and in vivo. Eur J Immunol 29:3478-3484.
27. Jaovisidha P, Peeples ME, Brees AA, Carpenter LR, Moy JN. 1999. Respiratory syncytial virus stimulates neutrophil degranulation and chemokine release. J Immunol 163:2816-2820.
28. Karron RA, Buonagurio DA, Georgiu AF, Whitehead SS, Adamus JE, Clements-Mann ML, Harris DB, Randolph VB, Udem SA, Murphy BR, Sidhu MS. 1997. Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: Clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant. Proc Natl Acad Sci USA 94:13961-13966.
29. Krilov LR. 2002a. Palivizumab in the prevention of respiratory syncytial virus disease. Exp Opin Biol Ther 2:763-769.
30. Krilov LR. 2002b. Safety issues related to the administration of ribavirin. Pediatr Infect Dis J 21:479-481.
31. Krusat T, Streckert HJ. 1997. Heparin-dependent attachment of respiratory syncytial virus (RSV) to host cells. Arch Virol 142:1247-1254.
32. Lalani AS, Masters J, Zeng W, Barrett J, Pannu R, Everett H, Arendt CW, McFadden G. 1999. Use of chemokine receptors by poxviruses. Science 286:1968-1971.
33. Langedijk JP, de Groot BL, Berendsen HJ, van Oirschot JT. 1998. Structural homology of the central conserved region of the attachment protein G of respiratory syncytial virus with the fourth subdomain of 55-kDa tumor necrosis factor receptor. Virology 243:293-302.
34. Lee B, Sharron M, Blanpain C, Doranz BJ, Vakili J, Setoh P, Berg E, Liu G, Guy HR, Durell SR, Parmentier M, Chang CN, Price K, Tsang M, Doms RW. 1999. Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function. J Biol Chem 274:9617-9626.
35. Lehner T. 2002. The role of CCR5 chemokine ligands and antibodies to CCR5 coreceptors in preventing HIV infection. Trends Immunol 23:347-351.
36. Liu J, Thorp SC. 2002. Cell surface heparan sulfate and its roles in assisting viral infections. Med Res Rev 22:1-25.
37. Locati M, Murphy PM. 1999. Chemokines and chemokine receptors: Biology and clinical relevance in inflammation and AIDS. Annu Rev Med 50:425-440.
38. Lusso P. 2002. HIV and chemokines: Implications for therapy and vaccine. Vaccine 20:1964-1967.
39. Malhotra R, Ward M, Bright H, Priest R, Foster MR, Hurle M, Blair E, Bird M. 2003. Isolation and characterisation of potential respiratory syncytial virus receptor(s) on epithelial cells. Microbes Infect 5:123-133.
40. Martin L, Blanpain C, Garnier P, Wittamer V, Parmentier M, Vita C. 2001. Structural and functional analysis of the RANTES-glycosaminoglycans interactions. Biochemistry 40:6303-6318.
41. Martinez I, Melero JA. 1998. Enhanced neutralization of human respiratory syncytial virus by mixtures of monoclonal antibodies to the attachment (G) glycoprotein. J Gen Virol 79:2215-2220.
42. Moser B, Loetscher P. 2001. Lymphocyte traffic control by chemokines. Nat Immunol 2:123-128.
43. Nardese V, Longhi R, Polo S, Sironi F, Arcelloni C, Paroni R, DeSantis C, Sarmientos P, Rizzi M, Bolognesi M, Pavone V, Lusso P. 2001. Structural determinants of CCR5 recognition and HIV-1 blockade in RANTES. Nat Struct Biol 8:611-615.
44. Noah TL, Ivins SS, Murphy P, Kazachkova I, Moats-Staats B, Henderson FW. 2002. Chemokines and inflammation in the nasal passages of infants with respiratory syncytial virus bronchiolitis. Clin Immunol 104:86-95.
45. Olsewska-Pazdrak B, Casola A, Saito T, Alam R, Crowe SE, Mei F, Ogra PL, Garofalo RP. 1998. Cell-specific expression of RANTES, MCP-1, and MIP-1alpha by lower airway epithlelial cells and eosinophils infected with respiratory syncytial virus. J Virol 72:4756-4764.
46. Pakianathan DR, Kuta EG, Artis DR, Skelton NJ, Hebert CA. 1997. Distinct but overlapping epitopes for the interaction of a CC-chemokine with CCR1, CCR3 and CCR5. Biochemistry 36:9642-9648.
47. Pastey MK, Gower TL, Spearman PW, Crowe JE, Jr., Graham BS. 2000. A RhoA-derived peptide inhibits syncytium formation induced by respiratory syncytial virus and parainfluenza virus type 3. Nat Med 6:35-40.
48. Proudfoot AE, Power CA, Hoogewerf AJ, Montjovent MO, Borlat F, Offord RE, Wells TN. 1996. Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist. J Biol Chem 271:2599-2603.
49. Proudfoot AE, Fritchley S, Borlat F, Shaw JP, Vilbois F, Zwahlen C, Trkola A, Marchant D, Clapham PR, Wells TN. 2001. The BBXB motif of RANTES is the principal site for heparin binding and controls receptor selectivity. J Biol Chem 276:10620-10626.
50. Proudfoot AE, Power CA, Rommel C, Wells TN. 2003. Strategies for chemokine antagonists as therapeutics. Sem Immunol 15:57-65.
51. Razinkov V, Gazumyan A, Nikitenko A, Ellestad G, Krishnamurthy G. 2001. RFI-641 inhibits entry of respiratory syncytial virus via interactions with fusion protein. Chem Biol 8:645-659.
52. Saito T, Deskin RW, Casola A, Haeberle H, Olszewska B, Ernst PB, Alam R, Ogra RL, Garofalo R. 1997. Respiratory syncytial virus induces selective protduction of the chemokine RANTES by upper airway epithelial cells. J Infect Dis 175:497-504.
53. Simmons G, Reeves JD, Hibbitts S, Stine JT, Gray PW, Proudfoot AE, Clapham PR. 2000. Co-receptor use by HIV and inhibition of HIV infection by chemokine receptor ligands. Immunol Rev 177:112-126.
54. Staunton DE, Merluzzi VJ, Rothlein R, Barton R, Marlin SD, Springer TA. 1989. A cell adhesion molecule, ICAM-1, is the major surface receptor for rhinoviruses. Cell 56:849-853.
55. Stellato C, Brummet ME, Plitt JR, Shahabuddin S, Baroody FM, Liu MC, Ponath PD, Beck LA. 2001. Expression of the C-C chemokine receptor CCR3 in human airway epithelial cells. J Immunol 166:1457-1461.
56. Tekkanat KK, Maassab H, Miller A, Berlin AA, Kunkel SL, Lukacs NW. 2002. RANTES (CCL5) production during primary respiratory syncytial virus infection exacerbates airway disease. Eur J Immunol 32:3276-3284.
57. Thomas LH, Friedland JS, Sharland M, Becker S. 1998. Respiratory syncytial virus-induced RANTES production from human bronchial epithelial cells is dependent on nuclear factor-kappa B nuclear binding and is inhibited by adenovirus-mediated expression of inhibitor of kappa B alpha. J Immunol 161:1007-1016.
58. Torrence PF, Powell LD. 2002. The quest for an efficacious antiviral for respiratory syncytial virus. Antivir Chem Chemother 13:325-344.
59. Tripp RA, Jones LP, Haynes LM, Zheng H, Murphy PM, Anderson LJ. 2001. CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat Immunol 2:732-738.
60. Walsh EE, Hruska J. 1983. Monoclonal antibodies to respiratory syncytial virus proteins: Identification of the fusion protein. J Virol 47:171-177.
61. Welliver RC, Garofalo RP, Ogra PL. 2002. Beta-chemokines, but neither T helper type 1 nor T helper type 2 cytokines, correlate with severity of illness during respiratory syncytial virus infection. Pediatr Infect Dis J 21:457-461.
62. Wright PF, Gharpure MA, Hodes DS, Chanock RM. 1973. Genetic studies of respiratory syncytial virus temperature-sensitive mutants. Arch Ges Virusforsch 41:238-247.
63. Zhang Y, Luxon BA, Casola A, Garofalo RP, Jamaluddin M, Brasier AR. 2001. Expression of respiratory syncytial virus-induced chemokine gene networks in lower airway epithelial cells revealed by cDNA microarrays. J Virol 75:9044-9058.